SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays. The company has successfully secured significant deals with industry giants, including Medtronic USA and Japan, marking a substantial milestone in its international expansion efforts..

新加坡，2024年2月20日/PRNewswire/-MediThinQ，一家专门从事扩展现实（XR）可穿戴手术显示器的韩国创业公司，作为第一家在全球推出XR手术显示器的亚洲创业公司，正在掀起一波浪潮。该公司已成功与美敦力（Medtronic USA）和日本（Japan）等行业巨头达成重大交易，标志着其国际扩张努力的一个重大里程碑。。

Continue Reading

继续阅读

MediThinQ’s Scopeye XR surgical display

MediThinQ的Scopeye XR手术显示器

In tandem, MediThinQ has secured a multimillion-dollar investment from JLK Technology, a Singapore-headquartered medical devices manufacturer, who will also help accelerate MediThinQ's mass production as its appointed manufacturer.

与此同时，MediThinQ获得了总部位于新加坡的医疗器械制造商JLK Technology的数百万美元投资，该制造商还将作为其指定制造商帮助加速MediThinQ的大规模生产。

MediThinQ's XR solutions present critical information directly in from of the surgeon's eyes, eliminating the need to divert attention to screens. The first of its kind in revolutionising how medical information is accessed in live surgeries, they are backed by best-in-class image fidelity, latency, reliability, and equipment compatibility..

MediThinQ的XR解决方案直接从外科医生的眼睛中呈现关键信息，无需将注意力转移到屏幕上。这是第一次在活体手术中彻底改变医疗信息的访问方式，它们拥有一流的图像保真度、延迟、可靠性和设备兼容性。。

In the United States and Japan, the world's two largest healthcare markets, MediThinQ's products will be exclusively distributed by Medtronic, underscoring global industry leaders' acknowledgement of the quality and effectiveness of MediThinQ's offerings. This strategic partnership represents a significant milestone in MediThinQ's path toward full-scale commercialisation and global expansion.Mr Seungjoon Im, Founder & CEO of MediThinQ, expressed his excitement, stating, 'We are proud of the groundbreaking technology we've cultivated over the past six years, which sets a new standard in the market.

在美国和日本这两个世界上最大的医疗保健市场，MediThinQ的产品将由美敦力独家分销，突显了全球行业领导者对MediThinQ产品质量和有效性的认可。这一战略伙伴关系是MediThinQ走向全面商业化和全球扩张道路上的一个重要里程碑。MediThinQ创始人兼首席执行官Seungjoon Im先生表达了他的兴奋之情，他说：“我们为过去六年来我们培养的开创性技术感到骄傲，这为市场树立了新的标准。

It's even more rewarding to see our innovations making their way into operating theatres worldwide. We extend our heartfelt appreciation to all our partners who have joined us on this transformative journey, and to VentureBlick for orchestrating these pivotal moments and connecting the dots behind the scenes.'Earlier this year, MediThinQ joined VentureBlick's Super Incubator programme – a unique blend of incubator, accelerator, and venture builder, offering tailored support for healthcare startups.

看到我们的创新进入世界各地的手术室，这更加令人感到欣慰。我们衷心感谢所有加入我们这一变革之旅的合作伙伴，感谢VentureBlick精心策划了这些关键时刻，并将幕后的点点滴滴联系起来。”今年早些时候，MediThinQ加入了VentureBlick的超级孵化器计划，该计划是孵化器、加速器和风险构建器的独特组合，为医疗保健初创公司提供量身定制的支持。

VentureBlick has since played a crucial role in elevating MediThinQ's global brand recognition, enhancing negotiation outcomes, raising funds, and positioning the company for continued success.MediThinQ's flagship products, Scopeye and MetaSCOPE, already hold regulatory approvals in key markets including the US (FDA), Europe (CE), Japan (PMDA), and Korea (KFDA).

此后，VentureBlick在提高MediThinQ的全球品牌知名度、提高谈判结果、筹集资金以及为公司持续成功定位方面发挥了至关重要的作用。MediThinQ的旗舰产品Scopeye和MetaSCOPE已经在美国（FDA）、欧洲（CE）、日本（PMDA）和韩国（KFDA）等关键市场获得监管部门的批准。

The technology has also been recognised as one of the top winners at the Medtronic APAC Innovation Challenge in 2022 and received a gold medal at the 2023 Edison Awards.Looking ahead, MediThinQ is gearing up to launch its next product line targeting the burgeoning Chinese market. It is also exploring applications beyond the .

该技术还被公认为2022年美敦力亚太创新挑战赛的最佳赢家之一，并在2023年爱迪生奖上获得金牌。展望未来，MediThinQ正准备推出针对新兴中国市场的下一条产品线。它还在探索应用程序之外。